**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Claudia Galvão Pedreira, Escola Bahiana de Medicina e Saúde Pública and Hospital Santo Antônio - Obras Sociais Irmã Dulce, Salvador, Bahia, Brazil

**Main Body of the Abstract**
INTRODUCTION: Hereditary Amyloidosis (ATTRv) is a severe, progressive, multisystemic autosomal dominant disease, leading to the deposition of amyloid in the eyes. Ocular involvement carries a risk of vision impairment. OBJECTIVES: Describe the prevalence of ocular findings in a sample of patients with ATTRv Amyloidosis in Salvador, Bahia. METHODS: A cross-sectional study, composed by confirmed ATTRv Amyloidosis patients at Bahiana School of Medicine and Public Health. Thirty-seven patients (74 eyes) underwent ophthalmological evaluation at Santo Antônio Hospital. RESULTS: Average age was 50 years (±15.8), 62% being female. Most frequent variants were Val50Met (49%) and Ile127Val (39%). Symptomatic comprised 73%, with 54% in PND stage I, followed by PND 0 (27%), PND II (13,5%), and PND III (5.4%). Dry eye was detected by Ocular Surface Disease Index in 58,4% and by Break-Up Time test in 91% of eyes. Conjunctival telangiectasia was observed in 78%, cataract were present in 44% of RE and 41% of LE. The average corrected visual acuity was 0.8 (±0.04) in RE and 0.87 (±0.03) in LE. Fundus examination revealed retinal deposits (82%), vitreous opacities (74%), and vascular tortuosity (40%). DISCUSSION: In addition to overall ophthalmological involvement, dry eye and vitreo-retinal findings appears to be higher than the available literature. Ocular findings may arise in asymptomatic patients: 86% had dry eyes, and 67% had vitreo-retinal involvement. Given that a significant number of patients exhibit ocular involvement, routine ophthalmological assessment is emphasized in the screening of ATTRv, contributing to the prevention of blindness and improve the quality of life.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Claudia Galvão Pedreira, Escola Bahiana de Medicina e Saúde Pública and Hospital Santo Antônio - Obras Sociais Irmã Dulce, Salvador, Bahia, Brazil

**Main Body of the Abstract**
**INTRODUCTION**: Hereditary Amyloidosis (ATTRv) is a severe, progressive, multisystemic autosomal dominant disease, leading to the deposition of amyloid in the eyes. Ocular involvement carries a risk of vision impairment. **OBJECTIVES:** Describe the prevalence of ocular findings in a sample of patients with ATTRv Amyloidosis in Salvador, Bahia. **METHODS**: A cross-sectional study, composed by confirmed ATTRv Amyloidosis patients at Bahiana School of Medicine and Public Health. Thirty-seven patients (74 eyes) underwent ophthalmological evaluation at Santo Antônio Hospital. **RESULTS:** Average age was 50 years (±15.8), 62% being female. Most frequent variants were Val50Met (49%) and Ile127Val (39%). Symptomatic comprised 73%, with 54% in PND stage I, followed by PND 0 (27%), PND II (13,5%), and PND III (5.4%). Dry eye was detected by Ocular Surface Disease Index in 58,4% and by Break-Up Time test in 91% of eyes. Conjunctival telangiectasia was observed in 78%, cataract were present in 44% of RE and 41% of LE. The average corrected visual acuity was 0.8 (±0.04) in RE and 0.87 (±0.03) in LE. Fundus examination revealed retinal deposits (82%), vitreous opacities (74%), and vascular tortuosity (40%). **DISCUSSION:** In addition to overall ophthalmological involvement, dry eye and vitreo-retinal findings appears to be higher than the available literature. Ocular findings may arise in asymptomatic patients: 86% had dry eyes, and 67% had vitreo-retinal involvement. Given that a significant number of patients exhibit ocular involvement, routine ophthalmological assessment is emphasized in the screening of ATTRv, contributing to the prevention of blindness and improve the quality of life.



Ocular Involvement in Transthyretin  Amyloidosis patients - Bahia State of Brazil PB29 (#224)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.